Ligand Pharmaceuticals
LGND
293.26
-3.68
-1.24%
Ligand Pharmaceuticals
US · LGND
#1920 by market cap
Listed 1970
293.26
-3.68
-1.24%
Live - 5344 symbols - heartbeat 509s ago
· 2026-10-08 07:00
Pre-market
292.00
-0.43%
After-hours
293.26
0.00%
- Market cap
- 5.85B
- P/E (TTM)i
- 30.20
- P/Bi
- 6.04
- EPSi
- 6.13
- Div yieldi
- 0.00%
- 52W posi
- 78%
Reader sentiment
Are you bullish or bearish on LGND?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 7.88, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +60.40% YoY
Margins
- Gross margin
- 94.57%
- Operating margin
- 17.61%
- Net margin
- 46.42%
Key ratios & quality
- Enterprise valuei
- 5.54B
- Altman Z-Scorei
- 7.88
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 251.45M | 120.28M | 163.56M | 241.54M | 196.25M | 131.31M | 167.13M | 268.09M |
| Gross profit | 245.12M | 108.94M | 133.14M | 179.37M | 143.42M | 120.80M | 156.06M | 253.54M |
| Selling & admin expenses | 37.73M | 41.88M | 60.01M | 46.79M | 70.06M | 52.79M | 78.65M | 92.45M |
| Research & development | 27.86M | 55.91M | 40.50M | 32.11M | 36.08M | 24.54M | 21.43M | 81.18M |
| Operating profit | 163.73M | -5.72M | 20.39M | 103.85M | 3.04M | 9.82M | 23.02M | 47.20M |
| Pretax profit | 173.33M | 796.64M | 1.29M | 72.21M | 36.01M | 63.66M | 2.52M | 158.96M |
| Tax | 30.01M | 167.34M | -5.31M | -4.15M | 41.23M | 9.84M | 6.55M | 34.51M |
| Net profit | 143.32M | 629.30M | -2.99M | 57.14M | -33.36M | 52.15M | -4.03M | 124.45M |
| Basic EPS | 7 | 33 | 0 | 3 | -2 | 3 | 0 | 6 |
| Diluted EPS | 5.96 | 31.85 | -0.18 | 3.31 | -1.98 | 2.94 | -0.22 | 6.13 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 45.33M | 47.63M | 115.46M | 59.67M | 51.72M | 63.69M |
| Gross profit | 40.48M | 44.72M | 111.66M | 56.67M | 48.45M | 60.48M |
| Selling & admin expenses | 18.80M | 20.18M | 28.45M | 25.03M | 20.84M | 29.12M |
| Research & development | 50.09M | 6.57M | 21.02M | 3.51M | 2.15M | 14.67M |
| Operating profit | -36.66M | 9.72M | 54.10M | 20.04M | 17.37M | 8.59M |
| Pretax profit | -50.18M | 11.22M | 141.14M | 56.78M | -24.26M | 64.30M |
| Tax | -7.73M | 6.38M | 23.86M | 12.00M | -10.91M | 15.80M |
| Net profit | -42.45M | 4.85M | 117.27M | 44.78M | -13.35M | 48.51M |
| Basic EPS | -2 | 0 | 6 | 2 | -1 | 2 |
| Diluted EPS | -2.21 | 0.24 | 5.68 | 2.12 | -0.67 | 2.22 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 870.54M | 1.12B | 500.56M | 464.75M | 263.60M | 237.43M | 331.56M | 832.27M |
| Cash & ST investments | 773.83M | 1.07B | 411.19M | 341.11M | 211.87M | 170.31M | 266.19M | 756.31M |
| Inventory | 7.12M | 7.30M | 26.49M | 27.33M | 13.29M | 23.97M | 14.11M | 9.13M |
| Total assets | 1.26B | 1.49B | 1.36B | 1.30B | 762.67M | 787.22M | 941.77M | 1.56B |
| Total current liabilities | 82.25M | 17.00M | 100.11M | 41.67M | 98.81M | 16.78M | 37.11M | 37.45M |
| Short-term debt | 26.43M | 1.26M | 8.48M | 1.41M | 77.41M | 410.00K | 1.27M | 1.10M |
| Long-term debt | 609.86M | 638.96M | 442.29M | 320.72M | -- | -- | -- | 446.19M |
| Total liabilities | 699,889,000.00 | 727,683,000.00 | 652,760,000.00 | 476,431,000.00 | 165,183,000.00 | 86,303,000.00 | 111,335,000.00 | 543,425,000.00 |
| Total equity | 560.91M | 767.23M | 709.53M | 821.16M | 597.49M | 700.91M | 830.44M | 1.02B |
| Retained earnings | -229.20M | 400.11M | 391.95M | 449.09M | 450.86M | 503.02M | 498.98M | 608.09M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 309.32M | 352.95M | 753.92M | 832.27M | 865.42M | 1.46B |
| Cash & ST investments | 208.90M | 255.30M | 676.94M | 756.31M | 791.56M | 1.37B |
| Inventory | 11.81M | 12.89M | 9.60M | 9.13M | 11.47M | 8.66M |
| Total assets | 905.44M | 948.60M | 1.48B | 1.56B | 1.53B | 2.19B |
| Total current liabilities | 58.68M | 64.73M | 30.54M | 37.45M | 40.67M | 46.74M |
| Short-term debt | 883.00K | 1.11M | 1.09M | 1.10M | 1.09M | 1.08M |
| Long-term debt | -- | -- | 445.49M | 446.19M | 446.90M | 1.13B |
| Total liabilities | 109,901,000.00 | 120,075,000.00 | 526,601,000.00 | 543,425,000.00 | 534,783,000.00 | 1,218,359,000.00 |
| Total equity | 795.53M | 828.53M | 950.17M | 1.02B | 997.32M | 967.52M |
| Retained earnings | 456.53M | 461.38M | 578.22M | 608.09M | 594.74M | 583.25M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 194.06M | -29.34M | 54.59M | 78.80M | 137.85M | 49.58M | 97.05M | 49.36M |
| Depreciation & amortization | 14.72M | 43.73M | 27.97M | 50.95M | 51.53M | 36.52M | 35.24M | 33.78M |
| Free cash flow | 183.17M | -31.89M | 50.13M | 70.04M | 119.93M | -4.27M | 77.41M | 38.05M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -122.87M | -453.05M | -78.00M | -- | 0 | 0 | 37.14M | -15.00M |
| Ending cash balance | 119.78M | 72.27M | 47.96M | 19.52M | 45.01M | 22.95M | 72.31M | 174.93M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -25.45M | 15.80M | 13.09M | 45.92M | 48.69M | 24.02M |
| Depreciation & amortization | 8.77M | 8.52M | 8.27M | 8.21M | 8.22M | 8.22M |
| Free cash flow | -27.48M | 15.59M | 4.68M | 45.26M | 48.46M | 21.35M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -15.00M | 0 | -- | -- |
| Ending cash balance | 47.99M | 67.67M | 139.38M | 174.93M | 115.09M | 1.01B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 29.26 | 94.76 | -0.40 | 7.47 | -4.70 | 8.03 | -0.53 | 13.47 |
| ROA %i | 14.84 | 45.67 | -0.21 | 4.30 | -3.24 | 6.73 | -0.47 | 9.95 |
| ROIC %i | 14.02 | 48.58 | 0.86 | 6.09 | -3.64 | 6.63 | -1.01 | 10.19 |
| 5-year avg ROE %i | 43.04 | 55.66 | 25.26 | 26.85 | 25.28 | 21.03 | 1.97 | 4.75 |
| EBIT margin %i | 88.13 | 692.03 | 9.06 | 24.15 | 19.27 | 48.98 | 3.32 | 61.05 |
| FCF / sales %i | 72.45 | -- | 26.89 | 25.27 | 61.11 | -- | 46.31 | 14.19 |
| Current ratioi | 10.58 | 66.09 | 5.00 | 11.15 | 2.67 | 14.15 | 8.93 | 22.23 |
| Quick ratioi | 10.09 | 65.38 | 4.70 | 10.39 | 2.50 | 12.49 | 8.32 | 21.83 |
| Debt / assetsi | 50.47 | 43.49 | 33.50 | 25.00 | 11.51 | 0.78 | 0.75 | 28.93 |
| LT debt / equityi | 108.73 | 84.58 | 63.13 | 39.33 | 1.73 | 0.82 | 0.70 | 44.28 |
| Interest coveragei | 4.59 | 23.29 | 0.62 | 3.41 | 21.02 | 98.04 | 1.83 | 34.71 |
| Revenue CAGR (3Y) %i | 51.78 | 3.35 | 5.05 | -1.33 | 17.72 | -7.06 | -11.55 | 10.96 |
| Net income CAGR (3Y) %i | -14.56 | -- | -- | -26.40 | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | 81.05 | -- | -16.60 | -27.42 | -- | -- | 3.39 | -31.80 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -16.56 | -9.46 | 5.42 | 13.47 | 17.13 | 21.96 |
| ROA %i | -14.58 | -8.36 | 4.00 | 9.95 | 12.60 | 12.58 |
| ROIC %i | -16.86 | -9.72 | 3.95 | 10.19 | 12.70 | 12.43 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -86.70 | -43.10 | 26.59 | 61.05 | 69.40 | 84.03 |
| FCF / sales %i | 18.59 | 20.34 | 8.18 | 14.19 | 41.53 | 41.22 |
| Current ratioi | 5.27 | 5.45 | 24.69 | 22.23 | 21.28 | 31.18 |
| Quick ratioi | 4.29 | 4.59 | 24.07 | 21.83 | 20.81 | 30.83 |
| Debt / assetsi | 0.49 | 0.61 | 30.54 | 28.93 | 29.50 | 51.76 |
| LT debt / equityi | 0.45 | 0.56 | 47.35 | 44.28 | 45.21 | 116.83 |
| Interest coveragei | -41.81 | -22.17 | 17.52 | 34.71 | 34.04 | 39.44 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Investing in the clinical development and commercialization of high-value medicines100.00%
Quote time 2026-10-08 07:00:15 · For reference only, not investment advice and not tailored to your situation.